SYS-CON MEDIA Authors: Pat Romanski, Elizabeth White, Yeshim Deniz, Nikita Ivanov, Sean Houghton

News Feed Item

Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

Summary

GBI Research has released its latest report for the pharmaceuticals industry, "Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019". There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 to 2019, the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and thiazolidinediones. Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is expected to be high, but this is unlikely to hinder their uptake. As a result, as well as an overall increase in the prevalent population, GBI Research believes that the value of the global market has the potential to grow to reach $38.8 billion by 2019.

Scope

- A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis
- In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
- Comprehensive review of the pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
- Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
- Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain
- Discussion of the drivers and barriers for market growth

Reasons to buy

- Understand the many different types of type 2 diabetes therapies on the market, from the older, established classes of treatment to newer, moderately superior types of drug, and their positions in the treatment algorithm
- Understand the strengths and weaknesses of each product
- Understand the scope of the pipeline, including which molecule types and mechanisms of action are prominent
- Observe trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for type 2 diabetes therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the type 2 diabetes therapeutics market.

Table of Contents

1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Epidemiology 10
2.2 Symptoms 10
2.3 Etiology 11
2.4 Pathophysiology 11
2.5 Co-morbidities and Complications 12
2.6 Classification 13
2.7 Prognosis 14
2.8 Diagnosis 14
2.9 Assessing Treatment Effectiveness 16
2.10 Treatment Algorithm 16
2.10.1 The Role of Insulin in Type 2 Diabetes 18
2.10.2 Non-insulin Diabetic Drugs 19
2.10.3 Other Drugs 21
3 Key Marketed Products 22
3.1 Metformin 22
3.2 DPP-4 Inhibitors 23
3.2.1 Januvia (sitagliptin) – Merck & Co 23
3.2.2 Tradjenta (linagliptin) – Boehringer Ingelheim 24
3.2.3 Onglyza (saxagliptin) – Bristol-Myers Squibb and AstraZeneca 25
3.2.4 Nesina (alogliptin) – Takeda 25
3.2.5 Galvus (vildagliptin) – Novartis 26
3.2.6 Tenelia (teneligliptin) – Daiichi Sankyo and Mitsubishi Tanabe 27
3.3 GLP-1 Agonists 28
3.3.1 Byetta and Bydureon (exenatide) – Bristol-Myers Squibb 28
3.3.2 Lyxumia (lixisenatide) – Sanofi 29
3.3.3 Victoza (liraglutide) – Novo Nordisk 30
3.4 Sulfonylureas 31
3.4.1 Glimepiride 31
3.4.2 Gliclazide 31
3.5 Thiazolidinediones 32
3.5.1 Actos (pioglitazone) – Takeda Pharmaceuticals Limited 32
3.5.2 Avandia (rosiglitazone) – GlaxoSmithKline 33
3.6 Long-Acting Insulins 34
3.6.1 Lantus (insulin glargine) – Sanofi 34
3.6.2 Levemir (insulin detemir) – Novo Nordisk 35
3.6.3 Tresiba and Ryzodeg (Insulin degludec) – Novo Nordisk 36
3.7 SGLT-2 Inhibitors 37
3.7.1 Forxiga (dapagliflozin) – Bristol-Myers Squibb 37
3.7.2 Invokana (canagliflozin) – Janssen 37
3.8 Heat Map for Marketed Products 38
4 Pipeline for Type 2 Diabetes 41
4.1 Overall Pipeline 41
4.2 Therapeutic Classes 42
4.3 Rate of Attrition 44
4.3.1 Failure Rate by Molecule Type 44
4.3.2 Failure Rate by Therapeutic Class 45
4.4 Reasons for Failure of Developmental Programs 48
4.5 Clinical Trial Duration 48
4.5.1 Duration by Molecule Type 48
4.5.2 Duration by Therapeutic Class 49
4.6 Clinical Trial Size 51
4.6.1 Clinical Trial Size by Molecule Type 52
4.6.2 Clinical Trial Size by Therapeutic Class 53
4.7 Promising Drugs in the Pipeline 55
4.7.1 LY-2189265 (dulaglutide) – Eli Lilly 55
4.7.2 Albiglutide – GlaxoSmithKline 55
4.7.3 LC15-044 (gemigliptin) – LG Life Sciences 56
4.7.4 TAK-875 – Takeda 56
4.7.5 Ipragliflozin – Astellas Pharma 57
4.7.6 LX-4211 – Lexicon Pharmaceuticals 57
4.7.7 Imeglimin – Poxel SA 58
4.7.8 CCX-140-B – ChemoCentryx 58
4.7.9 Semaglutide – Novo Nordisk A/S 59
4.7.10 PC-DAC Exendin-4 – ConjuChem Biotechnologies 59
4.8 Heat Map for Pipeline Products 59
4.9 Conclusion 62
5 Market Forecast to 2019 64
5.1 Global Market 64
5.1.1 Treatment Usage Patterns 64
5.1.2 Market Size 65
5.2 US 66
5.2.1 Treatment Usage Patterns 66
5.2.2 Annual Cost of Therapy 67
5.2.3 Market Size 67
5.3 Top Five Countries of Europe 68
5.3.1 Treatment Usage Patterns 68
5.3.2 Annual Cost of Therapy 69
5.3.3 Market Size 70
5.4 Japan 72
5.4.1 Treatment Usage Patterns 72
5.4.2 Annual Cost of Therapy 72
5.4.3 Market Size 73
5.5 Drivers and Barriers 73
5.5.1 Drivers 73
5.5.2 Barriers 74
6 Deals and Strategic Consolidations 75
6.1 Licensing Deals 75
6.1.1 TransTech Pharma Enters into Licensing Agreement with Forest Laboratories 78
6.1.2 Xoma Enters into Licensing Agreement with Les Laboratoires Servier for Xoma 052 78
6.1.3 Zealand Pharma Enters into a Licensing and Collaboration Agreement with Boehringer Ingelheim 78
6.1.4 Exelixis Enters into Licensing Agreement with Bristol-Myers Squibb for XL475 79
6.1.5 Prosidion Limited Enters into a Licensing Agreement with Eli Lilly and Company 79
6.1.6 Metabolex Enters into Licensing Agreement with Sanofi 79
6.1.7 Wellstat Enters into a License Agreement with Sanofi 79
6.1.8 CureDM and Lankenau Institute Enter into a Licensing Agreement with Sanofi 79
6.1.9 Metabolex Enters into a Development and Licensing Agreement with Janssen Pharmaceuticals 80
6.1.10 Dainippon Sumitomo Pharma Enters into Licensing Agreement with Intercept Pharma for INT-747 80
6.1.11 Ipsen Enters into Licensing Agreement with F. Hoffmann-La Roche for BIM 51077 80
6.1.12 Glenmark Pharma Enters into Licensing Agreement with Merck KGaA 80
6.1.13 Euroscreen Enters into Licensing Agreement with Janssen Pharmaceuticals 81
6.1.14 Phenomix Enters into Licensing Agreement with Chiesi Farmaceutici 81
6.1.15 Otsuka Pharma Enters into Licensing Agreement with Kyowa Hakko Kirin for Saxagliptin 81
6.1.16 Nastech Pharma Enters into Licensing Agreement with Amylin Pharma 81
6.1.17 Emisphere Technologies Enters into a Licensing Agreement with Novo Nordisk 81
6.1.18 Array BioPharma Enters into a Licensing Agreement with Amgen 82
6.1.19 Theratechnologies Enters into a Licensing Agreement with OctoPlus 82
6.1.20 Diabetica Enters into a Licensing Agreement with Amylin 82
6.1.21 Celtic Therapeutics Enters into a Licensing Agreement with Bellus Health 82
6.1.22 Aradigm Enters into a Licensing Agreement with Novo Nordisk 83
6.1.23 Santarus Enters into a License Agreement with Shore Therapeutics 83
6.1.24 Depomed Enters into a Licensing Agreement with Boehringer Ingelheim 83
6.1.25 Depomed Enters into a Licensing Agreement with Merck 83
6.1.26 Depomed Enters into a Licensing Agreement with Teva 84
6.2 Co-development Deals 84
6.2.1 Eli Lilly Enters into a Co-development Agreement with Boehringer Ingelheim 85
6.2.2 AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb 86
6.2.3 Metabolex Enters into a Co-development Agreement with Janssen Pharmaceuticals 86
6.2.4 Amylin Pharma Terminates Co-development Agreement with Eli Lilly for Exenatide 86
6.2.5 Isis Enters into a Collaboration Agreement with Janssen Pharmaceuticals 86
6.2.6 Neurocrine Biosciences Enters into a Collaboration Agreement with Boehringer Ingelheim 87
6.2.7 Intercept Pharma Enters into Co-development Agreement with Servier 87
6.2.8 Transition Therapeutics Enters into an Agreement with Eli Lilly 87
6.2.9 Ambrx Enters into a Co-Development Agreement with Bristol-Myers Squibb 87
6.2.10 Biocompatibles Enters into a Co-Development Agreement with AstraZeneca 88
7 Appendix 89
7.1 All Pipeline Drugs by Stage of Development 89
7.1.1 Discovery 89
7.1.2 Preclinical and IND-filed 91
7.1.3 Phase I 95
7.1.4 Phase II 98
7.1.5 Phase III and Pre-registration 102
7.1.6 Undisclosed 104
7.2 Market Forecasts to 2019 105
7.2.1 Global 105
7.2.2 US 105
7.2.3 UK 106
7.2.4 France 106
7.2.5 Germany 107
7.2.6 Italy 107
7.2.7 Spain 108
7.2.8 Japan 108
7.3 Market Definitions 109
7.4 Abbreviations 109
7.5 References for Heat Maps 112
7.6 References 114
7.7 Research Methodology 119
7.7.1 Coverage 119
7.7.2 Secondary Research 120
7.7.3 Primary Research 120
7.8 Therapeutic Landscape 121
7.9 Epidemiology-based Forecasting 121
7.10 Market Size by Geography 122
7.11 Geographical Landscape 123
7.12 Pipeline Analysis 123
7.13 Expert Panel Validation 123
7.14 Contact Us 123
7.15 Disclaimer 123

List of Tables

Table 1: The Relationship between HbA1c and Mean Blood Glucose 15
Table 2: Pipeline Drugs (Discovery) 89
Table 3: Pipeline Drugs (Preclinical and IND-filed) 91
Table 4: Pipeline Drugs (Phase I) 95
Table 5: Pipeline Drugs (Phase II) 98
Table 6: Pipeline Drugs (Phase III) 102
Table 7: Pipeline Drugs (Undisclosed stage of development) 104
Table 8: Type 2 Diabetes Therapeutics Market, Global, Market Forecast, 2012–2019 105
Table 9: Type 2 Diabetes Therapeutics Market, US, Market Forecast, 2012–2019 105
Table 10: Type 2 Diabetes Therapeutics Market, UK, Market Forecast, 2012–2019 106
Table 11: Type 2 Diabetes Therapeutics Market, France, Market Forecast, 2012–2019 106
Table 12: Type 2 Diabetes Therapeutics Market, Germany, Market Forecast, 2012–2019 107
Table 13: Type 2 Diabetes Therapeutics Market, Italy, Market Forecast, 2012–2019 107
Table 14: Type 2 Diabetes Therapeutics Market, Spain, Market Forecast, 2012–2019 108
Table 15: Type 2 Diabetes Therapeutics Market, Japan, Market Forecast, 2012–2019 108
Table 16: Type 2 Diabetes Therapeutics Market, Global, References for Heat Maps, 2013 112

List of Figures

Figure 1: Type 2 Diabetes Therapeutics Market, Global, Composite Treatment Algorithm, 2013 17
Figure 2: Type 2 Diabetes Therapeutics Market, Global, Sales of Januvia and Janumet ($m), 2006-2012 23
Figure 3: Type 2 Diabetes Therapeutics Market, Global, Sales of Onglyza ($m), 2009-2012 25
Figure 4: Type 2 Diabetes Therapeutics Market, Global, Sales of Galvus ($m), 2007–2012 26
Figure 5: Type 2 Diabetes Therapeutics Market, Global, Sales of Byetta ($m), 2005–2010 28
Figure 6: Type 2 Diabetes Therapeutics Market, Global, Sales of Victoza ($m), 2009–2012 30
Figure 7: Type 2 Diabetes Therapeutics Market, Global, Sales of Actos ($m), 2003-2011 32
Figure 8: Type 2 Diabetes Therapeutics Market, Global, Sales of Avandia ($m), 1999–2012 33
Figure 9: Type 2 Diabetes Therapeutics Market, Global, Sales of Lantus ($m), 2003-2012 34
Figure 10: Type 2 Diabetes Therapeutics Market, Global, Sales of Levemir (As reported by Novo Nordisk), 2008-2012 35
Figure 11: Type 2 Diabetes Therapeutics Market, Global, Heat Map of Marketed Products, 2013 39
Figure 12: Type 2 Diabetes Therapeutics Market, Global, Sales of Novel Products ($m, Years after Approval), 1998–2012 40
Figure 13: Type 2 Diabetes Therapeutics Pipeline Overview 41
Figure 14: Type 2 Diabetes Therapeutics Market, Global, Therapeutic Classes 42
Figure 15: Type 2 Diabetes Therapeutics Market, Global, Clinical Trial Failure Rate (%), 2006–2013 44
Figure 16: Type 2 Diabetes Therapeutics Market, Global, Failure Rate by Molecule Type, 2006–2013 45
Figure 17: Type 2 Diabetes Therapeutics Market, Global, Failure Rate by Therapeutic Class, 2006–2013 46
Figure 18: Type 2 Diabetes Therapeutics Market, Global, Reasons for Clinical Trial Failure (%), 2006–2013 48
Figure 19: Type 2 Diabetes Therapeutics Market, Global, Clinical Trial Duration, 2006–2013 49
Figure 20: Type 2 Diabetes Therapeutics Market, Mean Clinical Trial Duration by Therapeutic Class, Global, 2006–2013 50
Figure 21: Type 2 Diabetes Therapeutics Market, Mean and Median Clinical Trial Size, Global, 2006–2013 51
Figure 22: Type 2 Diabetes Therapeutics Market, Clinical Trial Size by Molecule Type, Global, 2006–2013 52
Figure 23: Type 2 Diabetes Therapeutics Market, Clinical Trial Size by Therapeutic Class, Global, 2006–2013 53
Figure 24: Type 2 Diabetes Therapeutics Market, Heat Map of Pipeline Products 60
Figure 25: Type 2 Diabetes Therapeutics Market, Global, Heat Map of Marketed Products, 2013 61
Figure 26: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns ('000), 2012–2019 64
Figure 27: Type 2 Diabetes Therapeutics Market, Global, Market Size ($m), 2012–2019 65
Figure 28: Type 2 Diabetes Therapeutics Market, US, Treatment Usage Patterns, 2012–2019 66
Figure 29: Type 2 Diabetes Therapeutics Market, Global, Market Size ($m), 2012–2019 67
Figure 30: Type 2 Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, 2012–2019 68
Figure 31: Type 2 Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2012–2019 69
Figure 32: Type 2 Diabetes Therapeutics Market, Top Five Countries of Europe, Market Size ($m), 2012–2019 71
Figure 33: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns, 2012–2019 72
Figure 34: Type 2 Diabetes Therapeutics Market, Japan, Market Size ($m), 2012–2019 73
Figure 35: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals by Country, 2006–2013 75
Figure 36: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals, 2006–2013 76
Figure 37: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals, 2006–2013 77
Figure 38: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals by Country, 2006–2013 84
Figure 39: Type 2 Diabetes Therapeutics Market, Global, Co-development Deals, 2006–2012 85
Figure 40: GBI Research Market Forecasting Model 122

Read the full report:
Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019
http://www.reportbuyer.com/pharma_healthcare/treatments/type_diabetes_therapeutics_market_2019_shifting_treatment_algorithm_intensified_competition_expected_drive_growth_2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Gridstore™, the leader in hyper-converged infrastructure purpose-built to optimize Microsoft workloads, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Gridstore™ is the leader in hyper-converged infrastructure purpose-built for Microsoft workloads and designed to accelerate applications in virtualized environments. Gridstore’s hyper-converged infrastructure is the ...
There's Big Data, then there's really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at Big Data Expo®, Hannah Smalltree, Director at Treasure Data, discussed how IoT, Big D...
DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete...
The 4th International DevOps Summit, co-located with16th International Cloud Expo – being held June 9-11, 2015, at the Javits Center in New York City, NY – announces that its Call for Papers is now open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's large...
The Internet of Things promises to transform businesses (and lives), but navigating the business and technical path to success can be difficult to understand. In his session at @ThingsExpo, Sean Lorenz, Technical Product Manager for Xively at LogMeIn, demonstrated how to approach creating broadly successful connected customer solutions using real world business transformation studies including New England BioLabs and more.
WebRTC defines no default signaling protocol, causing fragmentation between WebRTC silos. SIP and XMPP provide possibilities, but come with considerable complexity and are not designed for use in a web environment. In his session at @ThingsExpo, Matthew Hodgson, technical co-founder of the Matrix.org, discussed how Matrix is a new non-profit Open Source Project that defines both a new HTTP-based standard for VoIP & IM signaling and provides reference implementations.
DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete...
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at Internet of @ThingsExpo, James Kirkland, Chief Ar...
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, discussed single-value, geo-spatial, and log time series dat...
"SAP had made a big transition into the cloud as we believe it has significant value for our customers, drives innovation and is easy to consume. When you look at the SAP portfolio, SAP HANA is the underlying platform and it powers all of our platforms and all of our analytics," explained Thorsten Leiduck, VP ISVs & Digital Commerce at SAP, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SAP is delivering break-through innovation combined with fantastic user experience powered by the market-leading in-memory technology, SAP HANA. In his General Session at 15th Cloud Expo, Thorsten Leiduck, VP ISVs & Digital Commerce, SAP, discussed how SAP and partners provide cloud and hybrid cloud solutions as well as real-time Big Data offerings that help companies of all sizes and industries run better. SAP launched an application challenge to award the most innovative SAP HANA and SAP HANA...
Connected devices and the Internet of Things are getting significant momentum in 2014. In his session at Internet of @ThingsExpo, Jim Hunter, Chief Scientist & Technology Evangelist at Greenwave Systems, examined three key elements that together will drive mass adoption of the IoT before the end of 2015. The first element is the recent advent of robust open source protocols (like AllJoyn and WebRTC) that facilitate M2M communication. The second is broad availability of flexible, cost-effective ...
Scott Jenson leads a project called The Physical Web within the Chrome team at Google. Project members are working to take the scalability and openness of the web and use it to talk to the exponentially exploding range of smart devices. Nearly every company today working on the IoT comes up with the same basic solution: use my server and you'll be fine. But if we really believe there will be trillions of these devices, that just can't scale. We need a system that is open a scalable and by using ...
What do a firewall and a fortress have in common? They are no longer strong enough to protect the valuables housed inside. Like the walls of an old fortress, the cracks in the firewall are allowing the bad guys to slip in - unannounced and unnoticed. By the time these thieves get in, the damage is already done and the network is already compromised. Intellectual property is easily slipped out the back door leaving no trace of forced entry. If we want to reign in on these cybercriminals, it's hig...
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.